Presidential Greeting - American Society for Laser Medicine and ...

26 American Society for Laser Medicine and Surgery Abstracts
Study: A porcine model was chosen due to the morphological
similarities between swine skin and human skin. Allogeneic cells
were obtained by bone marrow aspiration from a donor pig.
Mesenchymal stem cells were isolated from the donor bone
marrow aspirate and transduced with a lentiviral vector
containing a fluorescent marker gene. One recipient pig was
placed under general anesthesia and 60 full thickness skin
wounds were made using a 10 mm punch biopsy. The wounds were
randomly assigned to two laser treatment regimens: laser CO 2/
MSC and laser Er:YAG/MSC. After AFL the stem cells were
pipetted into the vertical channels. Wounds were covered with an
occlusive polyurethane film dressing. Three punch and wedge
biopsies were taken from each group on days 5, 7, and 21.
Results: Labeled allogeneic bone marrow cells were observed in
papillary and reticular dermis on days 5 and 7 in both the Er:YAG
and CO 2 laser treated wounds. Some labeled cells were noted in
close proximity to the ablated vertical channels created by laser
treatment. Allogeneic cell showed persistence in the treated
wounds despite intense inflammation associated with the full
thickness wounds created.
Conclusion: Preliminary study suggests that ablative fractional
lasers may be useful technology to deliver mesenchymal stem
cells and this has broad implications for many branches of
medicine.
#81
A SPLIT-FACE STUDY INVESTIGATING
ALLUMERA COMBINED WITH MULTIPLE LASER
AND LIGHT SOURCES FOR
PHOTOREJUVENATION
Sabrina Fabi, Jennifer Peterson, Mitchel Goldman
Goldman Butterwick & Associates, Cosmetic Laser Surgery,
San Diego, CA
Background: Chronic exposure to sun can result in
photodamage manifested as fine lines/wrinkling, erythema,
tactile roughness, hyperpigmented macules and patches,
sallowness, skin laxity, and telangiectasias. Photodynamic
therapy (PDT) uses a photosensitizer such as aminolevulinic acid
or methyl aminolevulinic which is converted to protoporphyrin IX
in vivo. These photosensitizers concentrate in rapidly
proliferating cells, sebaceous glands, superficial melanin, and
vasculature. When visible light radiation is applied, reactive
oxygen species are generated. While originally indicated for the
treatment of nonhyperkeratotic actinic keratosis, improvement in
the signs of photoaging was noticed as an advantageous side
effect. Most commonly, blue fluorescent light or a red light
emitting diode is used to activate the photosensitizer; however,
any laser or light source that emits visible light radiation can be
used including the pulsed dye laser (PDL) and intense pulsed light
(IPL). When administering PDT in our practice, a sequence of four
laser and light sources are used: PDL, IPL, blue light, and red
light to work synergistically to activate the photosensitizer.
Photocure has developed Allumera cream (Photocure ASA, Oslo,
Norway), a precursor to photoactive protoporphyrins (PAP), that
enhances the skin appearance. This product is applied without
occlusion and allowed to incubate before activation by visible light
radiation. The purpose of this study is to investigate if the
addition of Allumera to a series of laser and light sources results in
further improvement of photoaging as compared to a placebo.
Study: The primary objective of this study was to evaluate the
efficacy of Allumera versus placebo combined with a series of laser
and light sources in the improvement of photoaging as measured
by the Global Score for Photoaging. Secondary objectives included:
improvement of fine/lines, hyperpigmentation, telangiectasias,
tactile roughness, erythema, sallowness, global evaluation of
response to treatment, patient evaluation of photoaging, patient
preference and patient satisfaction. A total of 20 patients were
randomized to receive split face treatment with Allumera cream
or placebo cream. On day 1 (Visit 1), day 30 (Visit 2), and day 60
(Visit 3), the face of study subjects was pretreated with
microdermabrasion and acetone wash, followed by randomized
treatment to half of the face with Allumera cream (Photocure
ASA, Oslo, Norway), and the other half with placebo cream, with
unoccluded application for 1 hour. Photoactivation followed with
first pulsed dye laser (PDL) to individual lesions, then intense
pulsed light (IPL) to the entire treatment area, and finally
treatment to entire face with both red and blue light sources.
Investigator assessment of global photoaging, fine lines/wrinkles,
hyperpigmentation, tactile roughness, sallowness,
telangiectasias, erythema, and adverse events (using a 5-point
scale) occurred prior to treatment at day 1 (Visit 1), day 30 (Visit
2), day 60 (Visit 3), and on day 90 (Visit 4). Patient questionnaires
were completed after day 1 (Visit 1), day 30 (Visit 2), and day 60
(Visit 3), for a total of 1 week after treatment. Standardized
photography was completed at day 1 (Visit 1) and day 90 (Visit 4).
Results: Eighteen of 20 patients (18 females), aged 32–64 years
old (mean 52.11), had completed visit 2 (day 30) of the study at the
time of data analysis; and 8 patients of those patients (8 females),
had completed visit 3 (day 60) by the time of data analysis. All
patients were Fitzpatrick skin types II–IV with moderate to
severe photodamage. Investigator assessment (using a 5 point
scale) comparing baseline to day 30 found a trend towards
improvement in global photoaging, fine lines/wrinkles,
hyperpigmentation, tactile roughness, sallowness,
telangiectasias, and erythema. Comparing baseline to day 60, a
statistical significance in improvement was noted in global
photoaging, fine lines/wrinkles, hyperpigmentation, tactile
roughness, and sallowness. There was no significant difference
noted in post-treatment pain, erythema and edema, between the
Allumera versus placebo-treated side by patients. Patient
assessment of pain, redness, swelling, and itching for seven days
following Visit 1 did not show a statistically significant difference
between the Allumera versus placebo-treated sides.
Conclusion: Treatment with Allumera shows a trend towards
improvement in global photoaging, fine lines/wrinkles,
hyperpigmentation, tactile roughness, sallowness,
telangiectasias, and erythema. Allumera is well tolerated by
patients and does not result in significant post-treatment pain,
erythema and edema compared to placebo. Preliminary data are
presented. This is a single-site study of a small cohort of patients
followed for an average of 45 days at the time of data analysis.
This study will be completed by February 28, 2011, by which time
we will have followed all 20 patients for a total of 120 days, and all
patients will have received an additional photodynamic therapy
session with Allumera.
#82
COMPARISON STUDY OF NON-ABLATIVE
FRACTIONAL TREATMENT WITH AND WITHOUT
ADVANCED SKIN COMPRESSION TECHNIQUE
Taro Kono, Motoko Nakata, Hiroyuki Sakurai,
Henry Chan
Tokyo Women’s Medical University, Tokyo, Japan; University of
Hong Kong, Hong Kong, China